IP Library Granted Patent US 11,160,488
Granted Patent B2
US 11,160,488 · App. 15/939,674 · Granted Nov 2, 2021

Reagents and methods for modulating cone photoreceptor activity

Inventors: Jay Neitz (Seattle, WA); Maureen Neitz (Seattle, WA); James A. Kuchenbecker (Seattle, WA); William W. Hauswirth (Gainesville, FL)
Assignees: Universty of Washington; University of Florida Research Foundation, Incorporated
A61B5/398A61B5/0036A61B5/0048A61B5/4836A61B5/4848A61B5/6821A61B5/7225A61K48/0058A61K48/0075A61N5/0622C07K14/005C12N7/00C12N15/85C12N15/86A61N2005/0652A61N2005/0661A61N2005/0663C12N2750/14132C12N2750/14143C12N2799/025C12N2830/008C12N2830/42C12N2840/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,160,488
App. No.
15/939,674
Granted
Nov 2, 2021
Kind
B2
Abstract

The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.

Claims (8)

1. A method for treating blue cone monochromacy in a primate, comprising administering to the eye of a primate suffering from blue cone monochromacy a recombinant adeno-associated virus (AAV) gene delivery vector comprising

(a) a promoter region, wherein the promoter region comprises an M opsin promoter sequence comprising the nucleic acid sequence of SEQ ID NO:2; and

(b) a gene encoding a therapeutic protein comprising the amino acid sequence of SEQ ID NO: 11;

wherein in vivo expression of the therapeutic protein in cone cells of the primate serves to restore visual capacity in the primate.

2. The method of claim 1 , wherein the visual capacity is selected from the group consisting of: a reduction or slowing of vision loss; improved visual acuity; and a decrease in abnormal sensitivity to bright lights.

3. The method of claim 2 , wherein the primate's response to the treatment is monitored.

4. The method of claim 1 , wherein the gene delivery vector further comprises an enhancer element upstream of the promoter, wherein the enhancer element comprises the nucleic acid sequence of SEQ ID NO: 51, and wherein the gene is operatively linked to the enhancer element.

5. The method of claim 1 , wherein the gene delivery vector further comprises an intron comprising a splice donor/acceptor region, wherein the intron is located downstream of the promoter region and is located upstream of the gene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: NEITZ, JAY; NEITZ, MAUREEN; KUCHENBECKER, JAMES A.
To: UNIVERSITY OF WASHINGTON
Reel/Frame 052839/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: HAUSWIRTH, WILLIAM W.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 052839/0571 →
Continuity (5)
Continuation 14837448 · Aug 27, 2015
Continuation 14075415 · Nov 8, 2013
Continuation 13395609
Provisional Application 61242587 · Sep 15, 2009
Related Publication 20180344197A1 · Dec 6, 2018
Cited By (1)
US 12,275,959